Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
Search
Close this search box.
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
Menu
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingReduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingAutologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingTACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingAB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingA Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingSequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant

Phase I Treatment of Urethral Strictures in Humans

  • Post author:
  • Post published:May 8, 2025
  • Post category:

When a scar, or stricture, forms along the urethra it impedes the flow of urine and causes other complications. James Yoo, M.D., Ph.D., and his team at Wake Forest University…

Continue ReadingPhase I Treatment of Urethral Strictures in Humans

Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingPhase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

  • Post author:
  • Post published:May 8, 2025
  • Post category:

Continue ReadingA Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS

  • Post author:
  • Post published:May 8, 2025
  • Post category:

BioEclipse combines two approaches - an immune cell called a cytokine-induced killer (CIK) cell and a virus engineered to kill cancer cells called an oncolytic virus (OV) - to create…

Continue ReadingPHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 33
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Multimedia Resources
  • Contact Us